CureVac NV (CVAC)

CureVac NV (CVAC)

Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

CureVac NV (CVAC) Profile

CureVac N.V., a clinical-stage biopharmaceutical firm, is focused on the development of a diverse range of revolutionary therapies based on messenger ribonucleic acid (mRNA). It is working to develop prophylactic vaccines, including CV7202, a prophylactic mRNA-based vaccine candidate against COVID-19; a vaccine for lassa yellow fever; a vaccine for the respiratory syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and immunisations against Rota, malaria, and universal influenza. Additionally, the company is developing RNA-based cancer immunotherapies, comprising ofCV8102 (BI 1361849), a self-adjuvanting mRNA vaccine in Phase 1 clinical trials for non-small cell lung cancer, and also tumour-associated antigens and shared neo-antigens. Additionally, the company is developing protein-based therapeutics for Cas9 gene editing, ophthalmic and respiratory illnesses, as well as therapeutic antibodies. The headquarters of the corporation are in T14 Bingen, Germany. Full Time Employees: 455 latest stock price29.860.00 (0.00%) At close: 04:00 PM as at 1/12/2022 EST. Market cap 5,585B USD. CureVac total assets for the quarter ending September 30, 2021, were $1.588B.

CureVac NV (CVAC.xnas) News
CureVac is developing CV2CoV, a preclinical second-generation mRNA vaccine potential, against SARS-CoV-2 in partnership with GlaxoSmithKline Plc (NYSE: GSK). In Q1 2022, the business plans to initiate a Phase 1 trial evaluating CV2CoV.

Holding cost
Trading hours in US Eastern Time
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30

Start Trading CureVac NV (CVAC)
with a Market Leader Today

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as acciones, commodities, y foreign exchange, y índices.

6 razones para operar CFD sobre acciones con FP Markets

Regulado en Australia
Bróker de forex y CFD

A largo o a corto

Increase your ability to profit in all market conditions Leverage options up to 20:1

Ejecución DMA
(Acceso directo al mercado)

Precios de acciones transparentes
y en tiempo real Control, funcionalidad y liquidez abundante
Total profundidad de mercado
y vista de órdenes en la cola

Plataformas avanzadas
& Technology

MT4, MT5, Webtrader & Iress with superior client portal

Soporte multilingüe 24/7

Award winning support & personal account managers

Exposición global

Márgenes bajos y comisiones competitivas en +10.000 productos en acciones globales en cuatro continentes

Gana dividendos

On long positions No ownership of physical shares necessary

Empieza a hacer trading
en cuestión de minutos.

Abre una cuenta ahora

bullet Accede a más de 10.000 instrumentos financieros
bullet Apertura y cierre automático de posiciones
bullet Noticias y agenda económica
bullet Indicadores técnicos y gráficos
bullet Muchas más herramientas incluidas

Al proporcionar su correo electrónico, usted acepta la política de privacidad de FP Markets y está de acuerdo en recibir futuros mensajes de marketing por parte de FP Markets. Puede darse de baja en cualquier momento.

Get instant Updates in Telegram
Mapa del sitio | © FP Markets 2022